Sacubitril

證據等級: L5

預測適應症: 5 個

Sacubitril: From Heart Failure (Sacubitril/Valsartan Combination) to Diabetic Nephropathy

Scoping note: The evidence pack lists 5 TxGNN-predicted indications. Ranks #1 (brain small vessel disease/ocular anomalies), #2 (HANAC syndrome), #4 (rheumatoid arthritis) and #5 (hemoglobinopathy) each have zero clinical trials, and where literature exists (rank #1, 19 papers) none of it mentions sacubitril — the evidence pack's own rationale flags these as likely TxGNN false positives with no mechanistic support. Rank #3, Diabetic Nephropathy, is the only candidate with actual clinical trials and mechanistically relevant literature, so this report focuses on it.

One-Sentence Summary

Sacubitril is the neprilysin-inhibitor component of the heart failure combination sacubitril/valsartan (LCZ696/Entresto); sacubitril itself has no marketing authorization on record in this evidence pack and its standalone mechanism-of-action data has not yet been catalogued. The TxGNN model predicts the sacubitril/valsartan combination may also benefit Diabetic Nephropathy, with 2 clinical trials (including 1 not-yet-recruiting Phase 4 RCT) and 17 publications — largely preclinical and mechanistic — currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Heart failure with reduced ejection fraction, as part of the sacubitril/valsartan combination (no sacubitril monotherapy indication on record)
Predicted New Indication	Diabetic Nephropathy
TxGNN Prediction Score	99.50%
Evidence Level	L3
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold (Research Question)

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for sacubitril itself is not available in this evidence pack. Based on known information, sacubitril is the neprilysin-inhibitor component of sacubitril/valsartan (LCZ696), whose efficacy in heart failure with reduced ejection fraction (HFrEF) is well established; mechanistically, this combination may also be applicable to diabetic nephropathy.

Neprilysin inhibition raises circulating natriuretic peptide (ANP/BNP) activity, which is theorized to reduce glomerular intracapillary pressure and exert anti-fibrotic and antioxidant effects; combined with valsartan's angiotensin-receptor blockade, this gives a plausible dual mechanism against diabetic kidney injury. Several rodent models (db/db mice, Zucker Obese rats, streptozotocin-diabetic rats) support reduced glomerulosclerosis, oxidative stress and NLRP3 inflammasome activity under sacubitril/valsartan treatment.

An important caveat: every piece of clinical and preclinical evidence below concerns the sacubitril/valsartan combination, not sacubitril as a single agent. Since sacubitril has no monotherapy indication or market presence on record here, any repurposing pathway for diabetic nephropathy would necessarily follow the already-marketed combination product, not sacubitril alone.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06501651	Phase 4	Not yet recruiting	297	Randomized, multicenter study (2:1 allocation) comparing sacubitril/valsartan vs. valsartan over 12 weeks in patients with essential hypertension and type 2 diabetic nephropathy; primary outcome tracks renal function change. No results yet available.
NCT04735354	N/A	Completed	268	Retrospective, non-interventional real-world EMR study of HFrEF patients on sacubitril/valsartan in India; documents prescribing/demographic patterns, not a diabetic-nephropathy-specific endpoint.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29661699	2018	RCT secondary analysis	The Lancet Diabetes & Endocrinology	Secondary analysis of the PARADIGM-HF trial assessing neprilysin inhibition's effect on renal function decline in patients with type 2 diabetes and chronic heart failure.
37549515	2023	Clinical (combination therapy study)	International Immunopharmacology	112 hypertensive diabetic nephropathy patients randomized to nifedipine + valsartan vs. nifedipine + sacubitril/valsartan; evaluates renal function outcomes.
40416927	2025	Clinical imaging study	Diabetes, Metabolic Syndrome and Obesity	BOLD-MRI study evaluating sacubitril/valsartan's renal protective effects in type 2 diabetic nephropathy patients.
37625003	2023	Review	Diabetes Care	Update on pillars of diabetic kidney disease therapy, situating RAAS/neprilysin-pathway agents within current management.
34441977	2021	Review	Journal of Clinical Medicine	Reviews the diabetes–heart failure–diabetic nephropathy relationship and relevant pharmacotherapies.
34734359	2023	Review	Heart Failure Reviews	Reviews disease-modifying drugs, including sacubitril/valsartan, in diabetic HFrEF patients.
35165832	2022	Review	Current Hypertension Reports	Reviews newer blood-pressure-lowering drugs developed for diabetic kidney disease and heart failure, including their mechanisms.
34431635	2021	Review	Revue Médicale Suisse	Discusses the potential role of sacubitril/valsartan in type 2 diabetes, including glycemic and renal protective signals.
35975848	2023	Review	Current Diabetes Reviews	Clinical review of existing and novel combination therapies for diabetic cardiorenal complications.
35992034	2022	Animal (preclinical, rat model)	Diabetes, Metabolic Syndrome and Obesity	Rat model of early diabetic nephropathy showing sacubitril/valsartan slows progression via NLRP3 inflammasome inhibition.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold (Research Question)

Rationale: Evidence for diabetic nephropathy currently consists of a secondary RCT analysis (PARADIGM-HF), one small combination-therapy clinical study, one imaging study, and multiple preclinical/review sources — but no completed trial with diabetic nephropathy as a primary endpoint, and the sole purpose-built Phase 4 RCT (NCT06501651) has not yet started recruiting. All evidence pertains to the sacubitril/valsartan combination, while sacubitril itself remains unmarketed in this jurisdiction with no MOA data on file.

To proceed, the following is needed:

Results from NCT06501651 (Phase 4 Hyper-Save Study) once recruitment completes
Sacubitril mechanism-of-action data (currently a High-severity data gap, DG002)
TFDA/regulatory package-insert warnings and contraindications (currently a Blocking data gap, DG001, required before any S1 safety pre-assessment)
Clarification of regulatory pathway: repurposing would apply to the marketed sacubitril/valsartan combination, not sacubitril monotherapy — combination-product regulatory status should be separately confirmed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.